Table Group l. Summary of thyroid abnormalities in the Marshallese, 1981. (Corrected = matched control value Est. thy. Total nodules Correc- ts Rongelap <10 10-18 >18 Total 22 12 33 67 17 3. 3 23 77.3 25.0 9.1 34.3 4.7 17.4 1.2 28.5 2 28.6 26.0 4 6 36.4 31.6 28.5 35.8 19 3 7 29 65.5 23.1 15.9 33.7 62.8 15.5 8.0 27.9 i 1 2 4 3.4 7.7 4.5 4,7 2.5 7.7 3.8 4.0 3 3 4.7 14.2 5.2 6.7 1 1 1.6 4.8 0.7 4.8 9.2 6.7 17 9.1 4.6 3. 1.8 1.1 4.6 275-450 190 135 217 av. Rong. + Ail. <10 29° 10-18 13. >18 44 Total 86 275-1150 190- 810 135- 335 482 av. Utirik <10 10-18 64 21 60-95 30-60 Total 164 51 av. >18 79° 30 9 11.4 3.5 4.5 8.3 6.1 6.0 ted % 3.6 8.3 5.4 5.2 No. % ted % 3 13.6 13.6 4 7 11.8 10.4 11.9 10.1 Total lesions Correc- No. 1 1 2 4 % Hypofunction** Correc- No. dose, rad Ailingnae <10 7 10-18 1 >18 ll Total 19 No. Carcinoma Correc- age 1954 810-1150T 335- 810 335 556 av. ted % subtracted.)}* ted % 88.0 17.4 13.2 38.7 26.0 1 1.3 i 1 9.0 5.2 8.8 3.0 37.3 30.8 3 10.3 10.3 9 8 11.4 9.3 (Jl. 9.0 73.1 15.5 19.1 36.9 0.6 3.5 Matched controls, unexposed <10 10-18 >18 Total 229 79 292 600 6 6 23 35 2.6 7.6 7.9 5.8 2 1 2 5 4.9 1.3 Q.7 0.8 1 \ 2 1.3 0.3 0.3 2.6TT 8.9 8.2 6.2 “The cancer estimates are possibly underestimated since all unoperated nodules were considered benign for these calculations. Occult carcinomas were not included under carcinoma. **No nodule cases with hypofunction are included. (See Tables 1 and 2, Appendix IV.) tThe lower dose estimates for the <10 group were used for in utero cases. TTNo correction necessary. -59 -